NO) mediates tumor necrosis factor (TNF)-␣ -induced activation of the transcription factor activating protein-1 (AP-1) in pulmonary microvessel endothelial monolayers (PEM). The DNA-binding activity of AP-1 was assessed using the electrophoretic mobility shift assay. TNF treatment (1,000 U/ml) for 4 h induced a significant increase in DNA binding of AP-1. The effects of TNF were prevented by the superoxide radical scavenger superoxide dismutase (SOD) (100 U/ml), the • NO synthase inhibitor aminoguanidine (100 M), the guanylate cyclase inhibitor ODQ (100 M), and the PKG inhibitors KT5823 (1 M) and 8-bromo-cyclic guanosine monophosphate (cGMP)-thioate (100 M). Spermine-NO (1 M) and L -arginine (400 M) prevented the aminoguanidine-induced ablation of AP-1 activation in response to TNF. Phosphorylation of H-Arg-Lys-Ile-Ser-Ala-Ser-Glu-Phe-Asp-Arg-Pro-Leu-Arg-OH (BPDEtide), a specific substrate for PKG, measured the activity of cGMP-dependent protein kinase (PKG). TNF for 0.5 h induced an increase in PKG activity that was prevented by aminoguanidine, ODQ, KT5823, and 8-bromo-cGMP-thioate; however, SOD had no effect. The PKG agonist 8-bromo-cGMP (100 M), when given alone, increased PKG activity but induced significant DNA-binding activity of AP-1 only when given in the ODQ ϩ TNF Group. SIN-1 (1 mM, a peroxynitrite agonist) increased DNA-binding activity of AP-1. SOD prevented SIN-1-induced AP-1 activation, a response similar to that of the SOD ϩ TNF Group. PEM were transfected with the chloramphenicol acetyltransferase (CAT) reporter plasmid pBLCAT2, which contains a regulation sequence responsive to AP-1. The pharmacologic profile of TNF-induced CAT activity was identical to TNF-induced DNA binding by AP-1. Thus, TNF-induced AP-1-dependent gene transcription is modulated by Tumor necrosis factor (TNF)-␣ is a mediator of experimental endotoxemia, sepsis, and adult respiratory distress syndrome (1) (2) (3) . TNF mediates a systemic and pulmonary endothelial inflammatory response characterized by altered expression of messenger RNA (mRNA) for proteins such as E-selectin (4, 5) , intercellular adhesion molecule-1 (4, 5) , vascular cell adhesion molecule-1 (4, 5) , tissue factor (6), macrophage colony-stimulating factor (7) , and nitric oxide (
• NO) synthase (8) . TNF mediates regulation of mRNA for phlogistic substances, at least in part, by altered activation of transcription factors such as activating protein-1 (AP-1) (9) . Activated AP-1 binds to regulatory sites on the 5 Ј and 3 Ј untranslated regions of introns, resulting in modulation of mRNA polymerase activity and subsequent effects on transcription of DNA into mRNA (6, 10, 11) . Thus, AP-1 can modulate induction of protein synthesis by modulation of specific mRNA sequences.
We have shown that TNF induces an endothelial dysfunction mediated, at least in part, by the increased activ-ity of reactive nitrogen species (12, 13) . Reactive nitrogen species activity in endothelial cells can be mediated, at least in part, by the following two pathways (4 (8, 14, 15) , resulting in synthesis of the catalytic factor cyclic guanosine monophosphate (cGMP) and increased activity of cGMP-dependent protein kinase G (PKG) (8, (16) (17) (18) . PKG is a serine-threonine kinase that can potentially modulate phosphorylation of molecules that regulate transcription, such as the AP-1 subcomponents cFOS and cJUN (10, 11, 16, 17) . Second, • NO or ONOO Ϫ can react directly with amino acids, resulting in altered function of the target protein (14) .
The role of • NO-mediated PKG activation during TNFinduced AP-1 activation is not known despite the fact that • NO agonists, via a PKG pathway, can increase AP-1 activity (17) . Gudi and colleages demonstrated that transfection of PKG into initially PKG-deficient cells induced the activation of AP-1 (16). Tabuchi and associates (19) demonstrated in cerebellar granule cells that
• NO agonistinduced nitrosylation of AP-1 inhibits its DNA-binding activity, suggesting
• NO indirectly activates AP-1 via alternate pathways such as PKG (19) and ONOO Ϫ (20) . Thus, the role of PKG in the activity of AP-1 may be dependent on the cell type, culturing conditions, and agents used to alter cGMP activity.
In a model of acute pulmonary endothelial dysfunction using TNF, a systematic investigation of the role of
• NOinduced, PKG-mediated activation of AP-1 has not been done. Thus, in the present study we investigated the role of
• NO and activation of PKG in TNF-induced activation of AP-1 in pulmonary endothelial cells.
Materials and Methods

Reagents
All reagents were obtained from Sigma Chemical Company (St. Louis, MO) unless otherwise noted.
Pulmonary Microvessel Endothelial Cell Culture
Bovine pulmonary microvessel endothelial cells derived from fresh calf lungs were obtained at the ninth passage (Vec Technologies, Rensselaer, NY). The cells were serially cultured, from nine to 23 passages, in Dulbecco's modified Eagle's medium (DMEM) (GIBCO BRL, Grand Island, NY) supplemented with 10% fetal bovine serum (Hyclone; Hyclone Laboratories, Logan, UT) and 1% nonessential amino acids (GIBCO BRL) (12, 13) .
Pulmonary microvessel endothelial monolayers (PEM) were maintained in 5% CO 2 plus humidified air at 37 Њ C and reached confluence within two to three population doublings (bovine PEM: 3 to 5 d). The preparations were identified as endothelial monolayers by: ( 1 ) the characteristic "cobblestone" appearance using contrast microscopy showing ( 2 ) the presence of Factor VIII-related antigen (indirect immunofluorescence), ( 3 ) the uptake of acylated low-density lipoproteins, and ( 4 ) the absence of smoothmuscle actin (indirect immunofluorescence).
Pharmacologic Reagents
We determined the lowest effective dose of a pharmacologic agent on the basis of our own preliminary studies or from studies obtained from the literature, verified by using assays and controls as discussed later.
TNF and inactivated TNF. Highly purified recombinant human TNF from Escherichia coli (Genzyme, Cambridge, MA) with a specific activity of 588-900 ϫ 10 8 U/ml was used at 1,000 U/ml (1, 12, 13) . The TNF had less than 14 pg of endotoxin contamination per 10 6 units of TNF activity by standard limulus assay. To control for endotoxin contamination and the possible effects of the TNF vehicle, TNF was heat-inactivated by boiling for 45 min (12, 13) .
• NO-related reagents. To test the role of • NO generation in the endothelial response to TNF,
• NO synthase activity was inhibited by coincubation with the • NO synthase substrate antagonist aminoguanidine (100 M; LC Laboratories, Woburn, MA) (12) . In addition, PEM were preincubated (i.e., 15 min before aminoguanidine ϩ TNF) with L -arginine (1 mM) to verify the effect of endogenous repletion of
• NO activity (12, 13) . We previously showed that similar doses of L -arginine and spermine-NO reversed the aminoguanidine-induced prevention of the increase in • NO and ONOO Ϫ during a 4-h incubation with TNF using pulmonary arterial endothelial cells (12) . NO 2 Ϫ /NO 3 Ϫ levels, an index of
• NO, were measured with a Nitrate/Nitrite Colometric Assay Kit (Cayman Chemical, Ann Arbor, MI), a two-step assay using nitrate reductase and Griess reagent (12, 13) .
In separate studies, the exogenous • NO donor spermine-NOATE (spermine-NO, 1 M; LC Laboratories) was used to further verify that the TNF effect was due to
• NO (12) . Spermine (1 M; LC Laboratories) was used as the inactive control for spermine-NO.
Peroxynitrite-related reagents. In separate studies, SIN-1 (1 mM; Calbiochem, San Diego, CA) was used to verify that the TNF effect was due to the simultaneous generation of superoxide anion ( (13, 22) . To verify antioxidant specificity, heatinactivated SOD (autoclaving SOD for 45 min) was coincubated with the TNF (13, 22) .
PKG-related reagents. To test the role of guanylate cyclase activity in the endothelial response to TNF, guanylate cyclase was inhibited by coincubation with ODQ (100 M; Alexis Corp., San Diego, CA) (18) . To test the role of PKG activity in the endothelial response to TNF, PKG activity was specifically inhibited by coincubation with the adenosine triphosphate (ATP)-binding site antagonist KT5823 (1 M; Calbiochem) (18, 23) or the cGMP-binding site antagonist 8-bromo-cGMP-thioate (100 M, Alexis Corp.). 8-Bromo-cGMP (100 M), a phosphodiesterase-resistant cGMP analog, was used both to verify that the effect of ODQ was due to inhibition of guanylate cyclase and to assess the effect of cGMP on the endothelium (16) . 
Treatments
Electrophoretic Mobility Shift Assay
Nuclear extracts. Nuclear extracts were prepared as previously described (24) . PEM were seeded (1 ϫ 10 6 ) in sixwell 35-mm plastic dishes and allowed to reach confluence (2 ϫ 10 6 cells) in 3 to 5 d. PEM were washed once with Tris-buffered saline, followed by treatment with buffer A (10 mM N -2-hydroxyethylpiperazine-N Ј -ethane sulfonic acid [Hepes], 10 mM KCl, 100 M ethylenediaminetetraacetic
, 1 g/ml leupeptin, 5 g/ml pepstatin, 5 g/ml antipain, 700 M phenylmethylsufonyl fluoride [PMSF], 5 g/ ml antitrypsin, 5 g/ml aprotinin, and 100 M benzamidine. The PEM were scraped using a rubber policeman. The lysate was placed in a test tube and incubated on ice for 15 min. After incubation, 25 l of Nonidet P-40 (10% solution) was added to 400 l of lysate and the test tube was vortexed for 10 s and centrifuged at 15,000 ϫ g for 30 s at 4ЊC. The pellet was resuspended in 40 l of buffer C (5 mM Hepes, 100 mM NaCl, 250 M EDTA, 250 M EGTA, 1 mM DTT, 1 g/ml leupeptin, 5 g/ml pepstatin, 5 g/ml antipain, 1.5 mM PMSF, 5 g/ml antitrypsin, 5 g/ ml aprotinin, and 100 M benzamidine) and shaken on ice for 15 min. The suspension was centrifuged at 15,000 ϫ g for 5 min at 4ЊC. The supernatant was aliquotted and stored at Ϫ70ЊC. A necessary protein concentration of Ͼ 1 g/l was determined using the Bradford assay.
Labeling of oligonucleotides. Oligonucleotide cognates for AP-1 (5Ј-CGC TTG ATG AGT CAG C-3Ј; Promega, Madison, WI) and nuclear factor (NF)-B (5Ј-AGT TGA GGG GAC TTT CCC AGG C-3Ј; Promega) were prepared using a modification of Promega Technical Bulletin #110. After the labeling of the oligonucleotides with ␥ 32 P-deoxyATP using T4 polynucleotide kinase, the unincorporated label was removed using Nick Spin Columns (Pharmacia, Piscataway, NJ). The oligonucleotide's final specific activity was 50,000 to 200,000 counts per minute (cpm)/l.
Electrophoretic mobility shift assay. The reaction mixture was composed of nuclear extract (5 g), ␥
32 P-oligonucleotide cognate (1 l), and 0.4 mg/ml of calf thymus DNA in a total volume of 20 l in binding buffer (50 mM TrisHCl, 250 mM NaCl, 2.5 mM EDTA, 2.5 mM DTT, and 20% glycerol, pH 7.5). The 5 g of extract was within the linear range of a curve obtained in preliminary studies that indicated that the increase in AP-1 DNA binding versus the amount of sample protein was similar between the Control and TNF Groups. The reaction mixture was incubated for 5 to 10 min at room temperature, loaded on a 6% polyacrylamide gel, and electrophoresed at 500 mA and 125 V for 3.5 h. The gel was dried at 37ЊC for 24 h and autoradiographed at Ϫ70ЊC (overnight or until an adequate signal developed).
Quantitation of autoradiographs. Autoradiographs were digitized using a scanner (Scan Jet 4C/T; Hewlett-Packard, Downers Grove, IL). The bands were analyzed with Sigma Scan/Image (Jandel Scientific Software, San Rafael, CA) and quantified by: fill area ϫ intensity ϭ total intensity units. The digitized data were within the linear range of a curve obtained in preliminary studies that indicated that the increase in density versus the amount of sample protein was similar between the Control and TNF Groups.
Assay of PKG
PKG activity in cell lysate was measured by the ␥ 32 P-ATP-mediated phosphorylation of the peptide substrate BPDEtide (16, 17) .
Preparation of sample. PEM were seeded (400,000 cells/ well) and grown until confluent in 35-mm well dishes. After the respective drug procedures, PEM were washed three times with ice-cold phosphate-buffered saline (PBS) (2 ml/well) and scraped with 500 l ice-cold homogenization buffer: potassium phosphate (10 mM, pH 6.8), EDTA (10 mM), 2-mercaptoethanol (10 mM), and 3-isobutylmethylxanthine (IBMX) (1 mM; Alexis). The cell suspension was vortexed (5 s) and immediately placed on ice. An aliquot (40 l) was removed for determination of cell counts. The remainder of the cell suspension was lysed by three sonications (a 10-s pulse) and clarified by centrifugation at 11,000 ϫ g (30 s, 4ЊC). The supernatant (sample) was snap-frozen with dry ice/2-propanol and stored at Ϫ70ЊC until used.
Activity of sample. The sample ( ) and incubated for 10 min on ice. The reaction was terminated by spotting aliquots (25 l) onto 2-cm 2 phosphocellulose filter paper (Whatman P81; Fisher Scientific, Pittsburgh, PA). The filter paper was washed three times in phosphoric acid (75 mM) and put into Ecoscint (10 ml; National Diagnostic, Atlanta, GA), and radioactivity was measured using a beta counter (Packard 2500 TR; Canberra Company, Downers Grove, IL). The cpm were corrected for cell counts and specific activity of the ␥ 32 P-ATP. The assay is specific for PKG (16, 17, 23) because: (1) BPDEtide (H-Arg-Lys-Ile-Ser-Ala-Ser-Glu-Phe-Asp-ArgPro-Leu-Arg-OH) contains a consensus sequence relatively specific for PKG-mediated phosphorylation, (2) PKI (0.9 M), the PKA inhibitor, was used in all assays, and (3) KT5823 and 8-bromo-cGMP-thioate prevented 8-bromocGMP-induced increases in phosphorylation in our system ( Table 1) .
Assay of PKA PKA activity in cell lysate was measured by the ␥ 32 P-ATPmediated phosphorylation of the peptide substrate KEMPtide (23) .
Preparation of sample.
The technique for the preparation of the samples was identical to the preparation technique described previously in the assay of PKG.
Activity of sample. The technique for the determination of the activity of the sample was identical for the PKG activity technique described earlier except for the following differences. First, the reaction mixture contained the PKA-specific substrate KEMPtide (150 m; Alexis) instead of BPDEtide. Second, the PKG inhibitor KT5823 (1.0 m) was included in all assays instead of PKI. Third, the positive control was 8-bromo-cyclic adenosine monophosphate (cAMP) (100 M) rather than 8-bromo-cGMP. Fourth, the activity was corrected for total protein (Bradford Assay; Bio-Rad, Hercules, CA) because it did not require separate studies as did the determination of cell counts.
The assay is specific for PKA (23) because: (1) KEMPtide (H-Leu-Arg-Arg-Ala-Ser-Leu-Gly-OH) contains the consensus sequence specific for PKA-mediated phosphorylation, (2) KT5823 (1.0 M), the PKG inhibitor, was used in all assays, and (3) the PKA antagonist KT5720 (1.0 M) prevented 8-bromo-cAMP (100 m)-induced increases in phosphorylation in our system (Table 2 ).
Transfection Studies: Biologic Relevance of Pulmonary Endothelial AP-1 Activation by TNF Plasmids. PEM were transfected with a plasmid with a response element interacting exclusively with AP-1 (kindly supplied by Dr. D. Leonardo, New York Medical Center, Tuxedo, NY) to demonstrate the functional role of AP-1 in TNF-induced gene expression in the pulmonary endothelium. The plasmid was constructed by linking a pBL-CAT2 plasmid (Accession #X64410) that contains a chloramphenicol acetyltransferase (CAT) reporter and a minimal thymidine kinase promoter (25) to an AP-1 binding site (5Ј-TGAGTCA). The efficiency of DNA expression was monitored by cotransfection with the reporter plasmid pCH-110 containing the ␤-galactosidase (GAL) gene driven by the active simian virus 40 promoter (Promega). CAT activity was assessed with enzyme-linked immunosorbent assay (Boehringer-Mannheim, Indianapolis, IN) and GAL was measured using the ␤-Galactosidase Enzyme Assay System (Promega). CAT activity was reported as the ratio of CAT/GAL activity (24) .
Transfection. Plasmids (1 g/l) were mixed with Tranfectam (Promega Technical Bulletin #116) in serum-free DMEM and were immediately added to PEM. The PEM were initially incubated with the plasmids for 2.5 h, overlaid with complete media, and grown for 48 h before treatment with TNF. 
Assay of Cell Viability
Trypan blue exclusion. PEM were seeded (2 ϫ 10 6 cells/ well) and grown until confluent in 100-mm well dishes. After the respective drug procedures, PEM were washed with PBS (2 ml) followed by treatment with 0.05% trypsin (1 ml) for 1 min at 37ЊC. The cells were then washed and suspended in PBS (5 ml). An aliquot of cell suspension (50 l) was combined with 0.4% trypan blue (50 l) for 3 min, then 20 l of the mixture was counted for cells using a hemocytometer. Cell viability was defined by the following formula: Cell viability ϭ (cells excluding trypan blue/ total cells) ϫ 100.
Cell number. Total cell numbers of PEM were determined as previously described in conjunction with the trypan exclusion studies.
Nuclear protein. Nuclear protein concentrations were determined in diluted samples with a Bradford Assay (Bio-Rad) (12) .
Statistics
A one-way analysis of variance was used to compare values among the treatments. If significance among treatments was noted, a Bonferroni multiple comparison test (post hoc) was used to determine significant differences among the groups (26) . A t test was used when appropriate. Each well and flask represents a single experiment. All data are reported as means Ϯ standard error of the mean. Significance was at P Ͻ 0.05.
Results
TNF Did Not Affect Cell Viability
The levels of cell counts, trypan blue exclusion, and nuclear protein concentrations were similar among the groups, indicating that the various treatments did not induce toxicity in the endothelial monolayer (e.g., Control: 3.7 Ϯ 0.1 versus TNF: 3. Figure 1 shows the time course for the TNF-induced increase in AP-1 activity. TNF from 0.5 to 4 h induced an augmentation in density of the AP-1 band (i.e., decrease in migration of the oligonucleotide probe) that became statistically significant at 4 h compared with the Control Group.
Role of • NO
TNF activated DNA binding of AP-1 via a • NO-dependent pathway. Figure 2 shows the effect of inhibition of
• NO synthase by aminoguanidine on TNF-induced enhancement of AP-1 DNA-binding activity. Figure 2A shows representative assays of nuclear lysates isolated from PEM incubated for 4 h with TNF, inactive TNF, aminoguanidine, L-arginine, and control media. Figure 2B shows the mean values (n ϭ 6 per group) of the groups represented in Figure 2A compared to the Control Group. TNF induced an increase in density of the AP-1 band at 4 h compared with the Control Group, which was not observed in the Inactive TNF Group. In the Aminoguanidine ϩ TNF Group, the AP-1 DNA-binding activity was similar to that of the Control Group but higher compared with the Aminoguanidine Group. In the L-Arginine ϩ Aminoguanidine ϩ TNF Group, TNF did induce an increase in AP-1 DNA-binding activity compared with the Control and L-Arginine ϩ Aminoguanidine Groups, indicating the specificity of aminoguanidine as an antagonist of L-arginine activity. There were no significant densities detected in the lanes loaded with free oligonucleotide and TNF ϩ 50ϫ cold oligonucleotide (data not shown). Thus, the data indicate that
• NO synthase activity and additional pathways mediate TNF-induced AP-1 activation.
The levels of • NO in the TNF Group We used spermine-NO because the pharmacologic profile of Figure 2 indicates that
• NO mediates the TNFinduced increase in AP-1 DNA-binding activity. Figure 2 shows the mean values (n ϭ 6 per group) after incubation with aminoguanidine, spermine-NO, spermine, and control media. The density of the AP-1 band increased in the Aminoguanidine ϩ Spermine-NO ϩ TNF Group compared with the Control Group. The density of the AP-1 band did not change in the Aminoguanidine ϩ TNF, Spermine-NO, and Spermine Groups compared with the Control Group. The density of the AP-1 band in the Aminoguanidine ϩ Spermine ϩ TNF Group was higher compared with the Aminoguanidine Group. Therefore, the data from the experiments using spermine-NO support the concept that
• NO synthase activity mediates TNF-induced AP-1 activation.
TNF recruited a concurrent pathway: DNA binding of AP-1 was inhibited by SOD. Our previous data indicate that a potential concurrent mediator of TNF-induced AP-1 activation is
• O 2 Ϫ (13, 14, 22). Thus, PEM were coincubated with SOD to remove the reactant
• O 2 Ϫ . Figure 3 shows the mean relative density of each group (n ϭ 3 per group) for nuclear lysates isolated 4 h after incubation with TNF, SOD, inactive SOD, and control media. The density of the AP-1 band increased in the TNF Group compared with the density in the Control Group. The density of the AP-1 band did not change in the SOD ϩ TNF Group compared with the density in the Control Group; however, the density of the AP-1 band did increase in the TNF ϩ Inactive SOD Group, indicating the specific O 2 Ϫ dismutase effect of the SOD treatment. There were no significant densities detected in the lanes loaded with free oligonucleotide (no sample) and TNF ϩ 50ϫ cold oligonucleotide (data not shown). Therefore, the pharmacologic profile derived from the results of Figures 2 and 3 Figure 4 shows a representative electrophoretic mobility shift assay (EMSA) (n ϭ 3 per group) of nuclear lysate isolated 4 h after incubation with SIN-1, SOD, and control media. The density of the AP-1 band increased in the SIN-1 Group compared with the density in the Control Group. The density of the AP-1 band did not change significantly in the SOD ϩ SIN-1 Group compared with the SOD Group. Thus, the data indicate that SIN-1-induced AP-1 activation is dependent on
Role of PKG TNF activated DNA binding of AP-1 via cGMP-PKG.
We studied the role of the guanylate cyclase and PKG in TNFinduced AP-1 DNA-binding activity because cGMP-medi- ated PKG activity is the classic effector pathway downstream from
• NO and ONOO Ϫ (8, 16). Figure 5 (n ϭ 5 per group) shows the effect of inhibition of guanylate cyclase by ODQ and inhibition of PKG by KT5823 and 8-bromocGMP-thioate on TNF-induced increases in AP-1 DNAbinding activity. There was an increase in the density of the AP-1 band in the TNF Group. The density of the AP-1 band did not change in the 8-bromo-cGMP, ODQ, and ODQ ϩ TNF Groups; however, the density of the AP-1 band increased in the ODQ ϩ 8-Bromo-cGMP ϩ TNF Group. These data indicate that 8-Bromo-cGMP alone had no effect on AP-1 activation but restored TNF-induced AP-1 activation in PEM also treated with ODQ; thus, the effect of ODQ was specific to inhibition of guanylate cyclase-mediated cGMP generation.
The density of the AP-1 band did not change in the groups treated with 8-bromo-cGMP-thioate and KT5823 compared with the density in the Control Group, indicating that TNF-induced AP-1 DNA-binding activity is indeed PKG-dependent.
SIN-1 activated DNA binding of AP-1 via cGMP-PKG.
We wanted to verify that SIN-1 induces a PKG-dependent increase in AP-1 activity. There was a greater density in the SIN Group (95.8 Ϯ 4.2 AP-1 relative density units) compared with the densities in the Control (37.5 Ϯ 3.5, AP-1 relative density units), KT5823 (38.2 Ϯ 17.0 AP-1 relative density units), and KT5823 ϩ SIN-1 (33.9 Ϯ 9.7 AP-1 relative density units) Groups.
TNF Increased PKG Activity in PEM Role of
• NO. We wanted to verify that the pharmacologic profile of TNF-induced,
• NO-mediated, AP-1 DNA-binding activity is supported by an appropriate pharmacologic profile of PKG activity. Table 1 shows the PKG values in the Control and treated groups (n ϭ 5-10 per group). TNF induced an increase in PKG activity at 0.5 h compared with the Control Group; however, there was no increase in PKG activity at 4 h. TNF did not induce a change in the PKG activity in the Aminoguanidine ϩ TNF Group but did induce a PKG activity increase in the L-Arginine ϩ Aminoguanidine ϩ TNF Group, indicating that
• NO synthase activity mediates TNF-induced PKG activation. TNF increased PKG activity in the SOD ϩ TNF Group, indicating that the TNF-induced PKG activation is not mediated by
• O 2
Ϫ
. Thus, the data in Table 1 support the concept that TNF-induced activation of PKG is mediated by
• NO. Role of guanylate cyclase. TNF did not increase PKG activity in the ODQ ϩ TNF Group, indicating that guany- late cyclase activity may mediate TNF-induced PKG activation. However, TNF did induce an increase in PKG activity in the ODQ ϩ 8-Bromo-cGMP ϩ TNF Group, indicating that cGMP mediates TNF-induced activation of PKG. In the KT5823 ϩ TNF and 8-Bromo-cGMP-thioate ϩ TNF Groups, there was no increase in PKG activity, indicating that TNF-induced increases in AP-1 activity were mediated by PKG.
TNF Did Not Alter PKA Activity in PEM
We wanted to verify that the pharmacologic manipulation of PKG activity indicated in Table 1 was not confounded by changes in PKA activity. Table 2 shows the PKA values in the Control and treated groups (n ϭ 5-10 per group). In the 8-Bromo-cAMP Group, there was an increase in PKA activity at 0.5 h but not at 4 h, which was prevented by KT5720 in the KT5720 ϩ 8-Bromo-cAMP Group. In the TNF and KT5823 ϩ TNF Groups, there was no change in PKA activity compared with the Control Group. Interestingly, there were trends for PKA activity to increase in the Aminoguanidine ϩ TNF and ODQ ϩ TNF Groups that were prevented by L-arginine (L-Arginine ϩ Aminoguanidine ϩ TNF Group) and 8-bromo-cGMP (8-Bromo-cGMP ϩ ODQ ϩ TNF Group), respectively. Thus, the data indicate that a 4-h treatment with TNF does not change the activity of PKA and that direct inhibition of PKG has no effect on the activity of PKA in response to TNF. cGMP without TNF Did Not Activate DNA Binding of AP- 1 We assessed the effect of 8-bromo-cGMP for 0.5 h on AP-1 DNA-binding activity because Table 1 indicates that TNF and 8-bromo-cGMP increased PKG activity only at 0.5 h. Figure 6 shows a representative EMSA (n ϭ 3 per group) of nuclear lysate isolated 0.5 and 4 h after incubation with no sample, TNF, 8-bromo-cGMP, and control media. In the 8-Bromo-cGMP Group, the density of the AP-1 band at 0.5 and 4 h did not increase compared with the Control Group (as opposed to the increases in densities after incubation with TNF at 4 h). Thus, the results in Figures 5 and 6 indicate that the cGMP-PKG-mediated increase in AP-1 DNA-binding activity is dependent on concurrent pathways induced by TNF.
TNF Induced AP-1-Dependent Pulmonary Endothelial Gene Transcription via
• NO, Guanylate Cyclase, and PKG
We wanted to verify that TNF-activated, AP-1-dependent gene regulation has a similar pharmacologic profile as AP-1 DNA-binding activity and PKG activation as indicated earlier. Figure 7 shows the CAT/GAL activity ratio of PEM cotransfected with the CAT (AP-1 construct) and the GAL (control construct) reporter plasmids. After transfection, the PEM were incubated for 4 h with TNF, aminoguanidine, L-arginine, ODQ, 8-bromo-cGMP, 8-bromocGMP-thioate, 8-bromo-cAMP, and control media (n ϭ 4-6 for each group). The CAT/GAL activity ratio was greater in the TNF Group than in the Control Group, which verifies the ability of TNF-activated AP-1 to alter gene expression. TNF did not induce an increase in the CAT/GAL activity ratio in the Aminoguanidine ϩ TNF Group but did increase the CAT/GAL activity ratio in the L-Arginine ϩ Aminoguanidine ϩ TNF Group, verifying that TNF-induced AP-1 activation is mediated by • NO synthase. TNF did not induce an increase in the CAT/ GAL activity ratio in the ODQ ϩ TNF and 8-BromocAMP ϩ ODQ ϩ TNF Groups; however, there was an increase in the CAT/GAL activity ratio in the 8-BromocGMP ϩ ODQ ϩ TNF Group. Moreover, 8-bromo-cGMP or 8-bromo-cAMP given alone had no effect on the CAT/ GAL activity ratio. These results indicate that cGMPinduced, AP-1-dependent gene expression is TNF-dependent and not related to cAMP. The CAT/GAL activity ratio was lower in the 8-Bromo-cGMP-thioate Group than in the Control Group and did not increase in response to TNF. Thus, the results shown in Figure 7 corroborate the conclusion that a ↑ [
• NO] → ↑ guanylate cyclase activity → ↑[cGMP] → ↑ PKG activity pathway mediates TNF-induced increases in AP-1-mediated gene transcription. In PEM transfected with only the GAL reporter there was no consistent effect of any of the treatments on GAL activity (data not shown), indicating no nonspecific effect on transcription.
TNF Activated DNA Binding of NF-B Independent of • NO
We studied the effect of TNF treatment on NF-B DNA binding activity to verify that the result of • NO synthase inhibition was not due to a nonspecific effect on TNFinduced DNA binding of transcription factors. Figure 8 shows a representative EMSA (n ϭ 2) of nuclear lysate isolated from PEM incubated for 4 h with TNF, aminoguanidine, L-arginine, and control media. The density of the NF-B band increased in all the groups treated with TNF, indicating that the effect of aminoguanidine on DNA binding is not due to nonspecific effects on transcription factor activity.
Discussion
• NO Mediated PKG Activation in Response to TNF
In the present study, TNF induced an increase in DNA binding of AP-1 that was associated with an increase in PKG activity. The TNF-induced increase in PKG activity was prevented by the • NO synthase inhibitor aminoguanidine, the guanylate cyclase inhibitor ODQ, and the PKG inhibitors KT5823 and 8-bromo-cGMP-thioate. L-Arginine reversed the effect of aminoguanidine on TNF-induced PKG activation. However, SOD did not prevent TNFinduced activation of PKG. Thus, the data indicate that • NO is necessary for TNF-induced activation of guanylate cyclase, which results in an increase in PKG activity in response to TNF.
• NO can directly activate guanylate cyclase (14) and increase cGMP, possibly via formation of RSNO (14, 15) .
PKG with Concurrent Pathways Mediated AP-1 Activation in Response to TNF
The TNF-induced increase in DNA binding of AP-1 was prevented by the guanylate cyclase inhibitor ODQ and the PKG inhibitors KT5823 and 8-bromo-cGMP-thioate. Thus, the data indicate that guanylate cyclase-mediated activation of PKG is necessary for TNF-induced activation of AP-1. Mechanisms for a change in activation of AP-1 include an alteration in the phosphorylation, redox state, and quantity of the AP-1 subcomponents (i.e., cFOS and cJUN ) (10, 11, 16, 17) . PKG may mediate the direct phosphorylation of the AP-1 subcomponents; however, a more likely mechanism is modulation of downstream transduction pathways (e.g., kinases, phosphatases, oxidant generation; 6, 10, 11, 27) by PKG.
The present data indicate that TNF-induced DNAbinding activity of AP-1 requires the ↑[
• NO] → ↑ guanylate cyclase activity → ↑[cGMP] → ↑ PKG activity pathway; however, the integration of PKG with other signal transduction pathways is noted. First, TNF induced an increase in PKG activity at 0.5 but not at 4 h; whereas DNA-binding activity of AP-1 increased significantly only between 2 and 4 h. Second, 8-bromo-cGMP given alone did not induce significant activation of AP-1 despite the fact that 8-bromo-cGMP increased activity of PKG. However, the same dose of 8-bromo-cGMP prevented the suppression of TNF-induced activation of PKG, AP-1, and gene transcription in the ODQ-treated groups. Finally, spermine-NO alone did not induce the activation of AP-1; however, the same dose of spermine-NO prevented the suppression of TNF-induced activation of AP-1 in the aminoguanidine-treated groups. These data indicate that the effect of cGMP is dependent on coincubation with TNF; thus, recruitment of pathways in addition to PKG is required for TNF-induced AP-1 activation.
Reactive Oxygen Species Are a Concurrent Pathway Mediating AP-1 Activation in Response to TNF
The results of the pharmacologic profile support the hypothesis that O 2 Ϫ , possibly via ONOO Ϫ , is a concurrent pathway that mediates the TNF-induced increase in DNAbinding activity of AP-1 (8, 14) for the following reasons. First, TNF-induced DNA-binding activity of AP-1 was prevented by the • NO synthase inhibitor aminoguanidine and the
• O 2 Ϫ scavenger SOD, reagents that prevent formation of the reactants for generation of ONOO Ϫ . Second, the inhibition of • NO synthase and SOD was specific to their respective effects on
• NO and • O 2 Ϫ because L-arginine reversed the effect of aminoguanidine and there was no effect of heat-inactivated SOD. SOD had no effect on the TNF-induced increase in PKG activity, indicating that the protective effect of SOD is via removal of the reactant • O 2 Ϫ , rather than the scavenging of • NO. Finally, KT5823 , is an additional pathway that mediates TNF-induced AP-1 activation is supported by the observation that SIN-1 induced an increase in AP-1 activation that was prevented by SOD. Also, we have new evidence using pulmonary microvessel endothelial cell lysates indicating that TNF caused an 11% increase in Western blot nitrotyrosine immunoreactivity, a probable indicator of ONOO Ϫ (29) . Finally, an exclusive role for
• NO during TNF-induced AP-1 activation is unlikely because spermine-NO alone had no effect on AP-1 activation but still reversed the effect of aminoguanidine on TNF-induced AP-1 activation. We showed previously that the identical treatment of PEM with spermine-NO induced the accumulation of extracellular
• NO to a final concentration of 2.9 M (similar to TNF-induced
• NO accumulation) (12) . This dose of spermine-NO will generate • NO at a rate of 25 to 0.8 nM/min based on a half-life of 39 min at 37ЊC (30) . The rate of
• NO accumulation and the extracellular site of action of SOD suggest that both
• NO and
Ϫ are generated by membrane-bound enzymes such as endothelial NO synthase (8) and nicotinamide adenine dinucleotide phosphate oxidase (28), respectively. Manna and coworkers showed that Mn-SOD prevents TNF-induced AP-1 activation in the human breast-cancer cell line MCF-7 (20) . It is well known that
• O 2 activates AP-1 (10), but its role with
• NO in response to TNF is not known. The
• NO ϩ • O 2 → ↑ ONOO Ϫ pathway can alter other components (6, 10, 11, 27, 31, 32) , which may contribute to TNF-induced AP-1 activation. Specifically, the role of ONOO Ϫ -induced oxidation, nitrosylation and nitration of AP-1 during TNF-induced AP-1 activation is not clear (10, 14) and is a subject of our future investigations. H 2 O 2 is not a critical component of TNF-induced AP-1 activation under our conditions because SOD mediates the dismutation of (14) . Another recruited-concurrent component required for TNF-induced AP-1 activation may be PKC. Our previous studies indicate that TNF activates PKC and our studies in progress indicate that the PKC inhibitor calphostin C (200-1,000 nM) significantly reduces TNF-induced DNAbinding activity of AP-1 (13, 22) . Phorbol ester-induced activation of PKC and reactive oxygen species classically modulates the activation of AP-1 (10, 27) via JUN aminotermini kinase activation (31) .
The data indicate that the effect of reactive nitrogen species inhibition was not due to a nonspecific effect on the TNF response because aminoguanidine and L-arginine did not affect the increase in NF-B activity in response to TNF and there was similar cell viability (i.e., percent of trypan blue, cell counts, and nuclear protein levels) among all the groups. It has been reported that • NO inhibits TNFinduced activation of NF-B both in systemic endothelial cells and in astrocytes (33) , possibly by stabilization of IB (5, 7, 21, 34) . Thus, the role of reactive nitrogen species on the activity of NF-B is dependent on the model used for investigation (4, 34) .
Potential for "Cross Talk" between PKG and PKA during TNF-Induced AP-1 Activation We needed to characterize the effect of the pharmacologic reagents used in the present study on the cAMP-PKA system because of the potential "cross talk" between the cGMP-PKG and cAMP-PKA pathways (23) . Our data indicate that the cAMP-PKA system does not confound interpretation of the role for PKG activation because neither KT5823 nor TNF altered PKA activity; whereas KT5823 prevented TNF-induced AP-1 activation. Moreover, 8-bromo-cAMP did not change the inhibitory effect of ODQ on TNF-induced gene transcription despite the fact that the same dose of 8-bromo-cAMP increased PKA activity in our system. Interestingly, there was a trend for aminoguanidine and ODQ to increase PKA activity in response to TNF that was prevented by L-arginine and 8-bromo-cGMP, respectively. Thus, the notion that
• NOinduced, cGMP-mediated suppression of PKA activity may have a permissive role in AP-1 activation in response to TNF cannot be ruled out. A TNF-induced increase in the level of cGMP can decrease the activity of PKA, possibly via the activation of the cGMP-stimulated phosphodiesterase Type II (23, 31) . These data underscore the complexities of signal transduction and indicate that the "cross talk" among specific pathways must be considered in a biologic response.
Reactive Nitrogen Species and PKG Mediated AP-1-Dependent Gene Transcription in Response to TNF
We verified the ability of TNF-activated AP-1 to alter gene regulation because TNF-treated PEM transfected with the AP-1-CAT reporter plasmid exhibited greater CAT/GAL activity than did the Control Group. The TNF-induced increase in CAT activity was dependent on the increase in AP-1 activity because the CAT activity was corrected by the expressed activity of an AP-1-independent reporter plasmid for GAL.
• NO synthase inhibition did not affect constitutive CAT activity; however, PKG inhibition decreased constitutive CAT activity. It is possible that subtle differences in the time course (0-4 h) for the effects of the antagonists caused the different constitutive expression of CAT. However, the inhibition of
• NO synthase, guanylate cyclase, and PKG prevented the increase in CAT activity in response to TNF. The effects of aminoguanidine and ODQ on the response to TNF were ablated by cotreatment with L-arginine and 8-bromo-cGMP, respectively. The specificity of the role of cGMP was further verified because 8-bromo-cAMP did not affect CAT expression, nor did it ablate the effect of ODQ. Thus, the data indicate that the ↑[
• NO] → ↑ guanylate cyclase activity → ↑ PKG activity pathway modulates AP-1-dependent gene transcription in response to TNF.
Summary
The data indicate the novel observation that TNF-induced DNA-binding and transcription activity of AP-1 is mediated by a ↑[
• NO] → ↑ guanylate cyclase activity → ↑[cGMP] → ↑ PKG activity pathway in pulmonary microvessel endothelial cells. Moreover, the TNF-induced activation of AP-1 is dependent on concurrent pathways via the activities of both
• NO and • O 2 Ϫ , perhaps as a result of the generation of ONOO Ϫ . Thus,
• NO-mediated increases in PKG activity are a mechanism for the modulation of AP-1-mediated gene transcription by TNF.
